Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium | Zendy

Kenneth H. Rand | Zendy; Herbert Houck | Zendy; Jared Silverman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daptomycin-reversible rifampicin resistance in vancomycin-resistant Enterococcus faecium

Author(s) -

Kenneth H. Rand,

Herbert Houck,

Jared Silverman

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm045

Subject(s) - daptomycin , enterococcus faecium , vancomycin , rifampicin , enterococcus , microbiology and biotechnology , vancomycin resistant enterococcus , medicine , gram positive bacterial infections , antibacterial agent , antibiotics , biology , bacteria , staphylococcus aureus , genetics

In a previous study, we observed marked synergy between daptomycin and rifampicin against 73% of rifampicin-resistant, vancomycin-resistant Enterococcus faecium (VRE), with approximately 100-fold reductions in rifampicin MICs observed at one-eighth to one-fourth daptomycin MIC. The purpose of this study was to determine whether the synergy between daptomycin and rifampicin could be explained by enhanced entry of rifampicin into the cell or was related to amino acid substitutions in the rifampicin-binding site in the beta subunit (rpo beta) of the RNA polymerase.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research